MarketCap
Facebook
X
Telegram
Fresenius Medical Care AG & Co. KGaA Income Statement 2025-2008 | FMS
Brief overview of financial results at Fresenius Medical Care AG & Co. KGaA
The figures are compared over a five-year interval. According to figures from Fresenius Medical Care AG & Co. KGaA, revenue changed from 17.9 billion euros to 19.6 billion euros over five years. Across the full period, sales moved by +9.9%; the average annual rate was 1.9%. The revenue trend is close to stagnation.
The five-year change in gross profit reached −9.2%: from 5.5 billion euros to 5 billion euros. Cost of revenue developed less favorably than sales and pressured gross profitability. At the margin level, the figure shifted from 31% to 25.6%. A lower margin indicates deterioration in the economics of the core business.
EBITDA changed from 4.1 billion euros to 3.3 billion euros (−18.7%). Operating performance weakened relative to revenue. EBITDA margin moved from 22.9% to 17%. The business retained less EBITDA from each unit of revenue.
Net profit was 1.2 billion euros at the start and 1.2 billion euros at the end. There was no meaningful strengthening in net profitability.
The market value of the business moved from 20.5 billion euros to 6.8 billion euros, or −66.6%. Investors responded cautiously to the improvement in the business.
Financial takeaway
The indicators point to a weaker financial profile. The financial profile benefits from stable net income. The main areas of concern are a lower gross margin, a softer top-line trend and lower investor confidence. Further direction will depend on top-line growth, operating profitability, and net income.
Annual Income Statement Fresenius Medical Care AG & Co. KGaA
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
6.83 B | 7.04 B | 5.68 B | 7.06 B | 9.47 B | 20.5 B | 22.4 B | 22.7 B | 30.3 B | 24.7 B | 27.1 B | 22.4 B | 21.7 B | 21.7 B | 21.4 B | 7.44 B | 6.28 B | 8.1 B |
Shares |
291 M | 293 M | 293 M | 293 M | 293 M | 605 M | 605 M | 613 M | 613 M | 611 M | 609 M | 605 M | 608 M | 610 M | 598 M | 297 M | 294 M | 293 M |
Historical Prices |
23.5 | 24 | 19.4 | 24.1 | 32.3 | 33.8 | 36.9 | 37 | 49.4 | 38.6 | 38.4 | 37 | 30.7 | 30.1 | 30.5 | 25.1 | 21.3 | 27.6 |
Net Income |
1.19 B | 741 M | 732 M | 894 M | 1.22 B | 1.16 B | 1.2 B | 1.98 B | 1.28 B | 1.18 B | 942 M | 860 M | 804 M | 897 M | 826 M | - | - | - |
Revenue |
19.6 B | 19.3 B | 19.5 B | 19.4 B | 17.6 B | 17.9 B | 17.5 B | 16.5 B | 17.8 B | 17 B | 15.3 B | 13 B | 10.6 B | 10.4 B | 9.87 B | - | - | - |
Cost of Revenue |
14.6 B | 14.6 B | 14.5 B | 14.5 B | 12.5 B | 12.3 B | 12.1 B | 11.4 B | 11.8 B | 11 B | 10.3 B | - | - | - | - | - | - | - |
Gross Profit |
- | - | - | 5.31 B | - | - | 5.4 B | 5.15 B | 6.02 B | 5.5 B | 4.88 B | 4.11 B | 3.43 B | 3.48 B | 3.49 B | - | - | - |
Operating Income |
1.83 B | 1.39 B | 1.37 B | 1.51 B | 1.85 B | 2.3 B | 2.27 B | 3.04 B | 2.36 B | 2.41 B | 2.13 B | - | - | - | - | - | - | - |
Interest Expense |
375 M | 393 M | 421 M | 359 M | 344 M | 407 M | 486 M | 438 M | -365 M | -363 M | - | - | - | - | - | - | - | - |
EBITDA |
3.33 B | 3.13 B | 3.12 B | 3.35 B | 3.48 B | 4.09 B | 3.86 B | 3.83 B | 3.1 B | 3.18 B | 2.76 B | 2.41 B | 2.08 B | 2.09 B | 2.01 B | - | - | - |
Operating Expenses |
- | - | - | - | - | 3.36 B | 17 B | 16 B | 17.4 B | 15.3 B | 14.4 B | 13.6 B | 12.4 B | 11.6 B | 10.8 B | - | - | - |
General and Administrative Expenses |
2.41 B | 2.48 B | 2.49 B | 2.37 B | 3.1 B | 3.16 B | 3.06 B | 2.87 B | 3.58 B | 2.89 B | 2.65 B | 2.17 B | 1.73 B | 1.68 B | 1.83 B | - | - | - |
All numbers in EUR currency
Quarterly Income Statement Fresenius Medical Care AG & Co. KGaA
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q4 | 2010-Q3 | 2010-Q2 | 2010-Q1 | 2009-Q4 | 2009-Q3 | 2009-Q2 | 2008-Q4 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
291 M | 292 M | 293 M | 293 M | 293 M | 293 M | 293 M | 293 M | 293 M | 293 M | 293 M | 293 M | - | - | - | 293 M | - | 293 M | 293 M | 293 M | - | 293 M | 293 M | 298 M | - | 301 M | 303 M | 307 M | - | 306 M | 306 M | 306 M | - | 307 M | 307 M | 307 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 297 M | 297 M | 296 M | 296 M | 294 M | 295 M | 294 M | 293 M |
Net Income |
1.19 B | 327 M | 272 M | 190 M | 741 M | 264 M | 240 M | 118 M | 732 M | 147 M | 195 M | 134 M | - | - | - | 212 M | - | 331 M | 280 M | 304 M | - | 420 M | 427 M | 350 M | - | 392 M | 315 M | 328 M | - | 349 M | 1.06 B | 330 M | - | 371 M | 338 M | 377 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
19.6 B | 4.88 B | 4.79 B | 4.88 B | 19.3 B | 4.76 B | 4.77 B | 4.72 B | 19.5 B | 4.94 B | 4.83 B | 4.7 B | - | - | - | 4.55 B | - | 4.44 B | 4.32 B | 4.21 B | - | 4.41 B | 4.56 B | 4.49 B | - | 4.42 B | 4.35 B | 4.13 B | - | 4.06 B | 4.21 B | 3.98 B | - | 4.34 B | 4.47 B | 4.55 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
14.6 B | 3.64 B | 3.58 B | 3.7 B | 14.6 B | 3.61 B | 3.6 B | 3.55 B | 14.5 B | 3.71 B | 3.63 B | 3.56 B | - | - | - | 3.29 B | - | 3.17 B | 3.04 B | 3 B | - | 3.05 B | 3.14 B | 3.1 B | - | 3.07 B | 3.01 B | 2.87 B | - | 2.79 B | 2.91 B | 2.77 B | - | 2.91 B | 2.98 B | 2.96 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.26 B | - | 1.27 B | 1.28 B | 1.21 B | - | 1.36 B | 1.41 B | 1.39 B | - | 1.35 B | 1.33 B | 1.27 B | - | 1.27 B | 1.3 B | 1.2 B | - | 1.42 B | 1.5 B | 1.59 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
1.83 B | 477 M | 425 M | 331 M | 1.39 B | 463 M | 425 M | 246 M | 1.37 B | 324 M | 357 M | 261 M | - | - | - | 348 M | - | 505 M | 424 M | 474 M | - | 632 M | 656 M | 555 M | - | 595 M | 521 M | 537 M | - | 527 M | 1.4 B | 497 M | - | 609 M | 583 M | 651 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
375 M | - | - | - | 393 M | - | - | - | 421 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 105 M | 114 M | -108 M | - | 75.9 M | -84.7 M | -82.9 M | - | -86.1 M | -95 M | -92.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
3.33 B | 1.6 B | 1.19 B | 726 M | 3.13 B | 1.73 B | 1.32 B | 758 M | 3.12 B | 1.65 B | 1.23 B | 699 M | - | - | - | 767 M | - | 505 M | 424 M | 862 M | - | 632 M | 656 M | 956 M | - | 595 M | 521 M | 899 M | - | 527 M | 1.4 B | 497 M | - | 609 M | 583 M | 651 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
2.41 B | 519 M | 608 M | 560 M | 2.48 B | 556 M | 580 M | 585 M | 2.49 B | 794 M | 775 M | 782 M | - | - | - | 871 M | - | 731 M | 830 M | 712 M | - | 707 M | 711 M | 810 M | - | 731 M | 795 M | 720 M | - | 743 M | 715 M | 679 M | - | 802 M | 904 M | 923 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in EUR currency
The income statement is one of the three key financial reports of a company Fresenius Medical Care AG & Co. KGaA (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
China
USA
Russia
Britain
